Drug intelligence / Profile preview

xestospongin C

Development stage
Unknown
Modality
Small Molecules
Administration
In Vitro (primarily Cell-based/research Use)
01

Overview

Xestospongin C is a marine-derived macrocyclic bis-1-oxaquinolizidine natural product, first identified from *Xestospongia* sponges. It acts as a **potent, membrane-permeable antagonist of the inositol-1,4,5-trisphosphate receptor (IP3 receptor)**, thereby inhibiting IP3-mediated Ca2+ release from intracellular stores such as the endoplasmic and sarcoplasmic reticulum. Xestospongin C has been shown to block the IP3 receptor with nanomolar potency and is ~30-fold selective over the ryanodine receptor. It also inhibits the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps at similar concentrations, thus it is not strictly selective for IP3 receptors. Xestospongin C has been primarily used as a **research tool** for investigating intracellular calcium signaling but is not approved for clinical use in humans or animals[1][2][3][5][7].

Other names
xestospongin CXeCAraguspongine E
02

Targets

IP3R (Inositol Trisphosphate Receptor)ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)CaV (Voltage-gated calcium channel protein complex)Kir (Inward-rectifier potassium channels)

Beyond the preview

Go deeper on xestospongin C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on xestospongin C.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call